enGene HoldingsNASDAQ: ENGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

01 February 2022

Next earnings report:

31 December 2024

Last dividends:

N/A

Next dividends:

N/A
$408.99 M
-48%vs. 3y high
62%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 25 Oct 2024 21:46:44 GMT
$9.25-$0.20(-2.12%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ENGN Latest News

enGene Announces $60 Million Private Placement Financing
businesswire.com25 October 2024 Sentiment: POSITIVE

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of.

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
businesswire.com26 September 2024 Sentiment: POSITIVE

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Today, the Company announced preliminary data from 21.

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
businesswire.com14 June 2024 Sentiment: POSITIVE

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update. “Our $200 million private placement in February positioned us well to execute our p.

What type of business is enGene Holdings?

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

What sector is enGene Holdings in?

enGene Holdings is in the Healthcare sector

What industry is enGene Holdings in?

enGene Holdings is in the Biotechnology industry

What country is enGene Holdings from?

enGene Holdings is headquartered in Canada

When did enGene Holdings go public?

enGene Holdings initial public offering (IPO) was on 01 February 2022

What is enGene Holdings website?

https://www.engene.com

Is enGene Holdings in the S&P 500?

No, enGene Holdings is not included in the S&P 500 index

Is enGene Holdings in the NASDAQ 100?

No, enGene Holdings is not included in the NASDAQ 100 index

Is enGene Holdings in the Dow Jones?

No, enGene Holdings is not included in the Dow Jones index

When was enGene Holdings the previous earnings report?

No data

When does enGene Holdings earnings report?

The next expected earnings date for enGene Holdings is 31 December 2024